LYNPARZA® Approved in the EU for Treatment of BRCA1/2-Mutated Metastatic Castration-Resistant Prostate Cancer Pharmaceutical Investing
LYNPARZA® in Combination with Bevacizumab Approved in the EU as First-Line Maintenance Treatment for HRD-Positive Advanced Ovarian Cancer Pharmaceutical Investing
Ionis and Akcea announce that Pfizer has initiated a Phase 2b clinical study of vupanorsen Pharmaceutical Investing
Bristol Myers Squibb Announces Deucravacitinib Demonstrated Superiority to Placebo and Otezla® in Pivotal Phase 3 Psoriasis Study Biotech Investing
European Medicines Agency Validates Marketing Application for Filgotinib for the Treatment of Ulcerative Colitis Biotech Investing
2nd Annual Gabelli Funds - Columbia Business School Healthcare Symposium - Friday, November 13, 2020 Pharmaceutical Investing
